

- a2
cont
63. The polynucleotide of claim 62, wherein said heterologous polynucleotide encodes a heterologous polypeptide.
64. The polynucleotide of claim 49, wherein said polynucleotide is fused to a heterologous polynucleotide.
65. The polynucleotide of claim 64, wherein said heterologous polynucleotide encodes a heterologous polypeptide.--

Add B3

Remarks

No new matter has been added by way of this amendment. Following entry of this amendment, claims 1 and 6-65 are pending in the application. Claims 20-65 have been substituted for canceled claims 2-5 to more clearly define the invention. Support for claims 20-65 can be found throughout the specification and original claims. In particular, support for claims 20-65 can be found, *inter alia*, at Figure 1; SEQ ID NOs:1 and 2; page 5, lines 15-21; page 11, line 29 to page 12, line 2 and lines 25-28; page 13, lines 3-12; page 17, lines 10-12 and 14-17; page 29, lines 20-23 and 25-28; page 15, line 10 to page 16 line 4 and page 32, line 25 to page 33, line 33. Claims 1, 6-10, 16, and 20-65 represent the invention of Group I, which is provisionally elected in the reply to the restriction requirement filed herewith.


The specification has also been amended to incorporate the current address for the ATCC.

It is not believed that extensions of time are required, beyond those that may otherwise be provided for in accompanying documents. However, if additional extensions of time are

necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Kimberlin L. Morley
Attorney for Applicants
Registration No. 35,391

Date: July 22, 1998

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005
(202) 371-2600